Get started
Author

Emily Jarvis

Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials
2024 · Florian Wagenlehner, Caroline R Perry, et al. · The Lancet · 117
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)
2022 · Jatin Patel, Damon Bass, et al. · European Respiratory Journal · 59
PDF
Use of autologous 99m Technetium-labelled neutrophils to quantify lung neutrophil clearance in COPD
2019 · Nicola Tregay, Malcolm Begg, et al. · Thorax · 29
PDF
An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects
2019 · Andrew W. Harrell, Robert Wilson, et al. · Drug Metabolism and Disposition · 27
PDF
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome
2023 · Malcolm Begg, Augustin Amour, et al. · Pulmonary Pharmacology & Therapeutics · 23
Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials
2021 · Malcolm Begg, J Nicole Hamblin, et al. · International Journal of COPD · 20
PDF
An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial
2021 · Anthony Cahn, J Nicole Hamblin, et al. · International Journal of COPD · 19
PDF
Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects
2018 · Robert Wilson, Emily Jarvis, et al. · Clinical Therapeutics · 17
Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection
2025 · Florian Wagenlehner, Caroline R Perry, et al. · Future Microbiology · 8
Mass spectrometry detection of inhaled drug in distal fibrotic lung
2022 · Theresia Mikolasch, Eunice Obella, et al. · Respiratory Research · 4
PDF
Investigation into the Acceptability of Moderate-to-Large Volume Subcutaneous Injections in Healthy Volunteers: Results from a Single-Center Randomized Controlled Study
2024 · Chika Akinseye, Andrew Fiorini, et al. · Medical Devices Evidence and Research · 3
PDF
2831. Efficacy and Safety of Gepotidacin for Uncomplicated Urinary Tract Infection: Pooled Subgroup Analyses of the EAGLE-2 and EAGLE-3 Randomized Phase 3 Trials
2023 · Thomas M Hooton, Caroline R Perry, et al. · Open Forum Infectious Diseases · 2
PDF
P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3)
2023 · Florian Wagenlehner, Caroline R Perry, et al. · JAC-Antimicrobial Resistance · 2
PDF
2837. Impact of Regulatory Guidelines on Therapeutic, Clinical, and Microbiological Success Rates in Uncomplicated Urinary Tract Infection: Results from a Two Phase 3 Randomized Controlled Trials of Oral Gepotidacin (EAGLE-2 and EAGLE-3)
2023 · Florian Wagenlehner, Caroline R Perry, et al. · Open Forum Infectious Diseases · 1
PDF
2832. Gepotidacin Efficacy in E. coli Drug-Resistant Phenotypes: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection
2023 · Thomas M Hooton, Caroline R Perry, et al. · Open Forum Infectious Diseases · 1
PDF
Late Breaking Abstract - Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry demonstrates inhaled drug deposition in transbronchial cryobiopsy samples of patients with Interstitial Lung Disease (ILD)
2019 · Theresia Mikolasch, Peter S. Marshall, et al. · European Respiratory Journal · 1
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3
2025 · Florian Wagenlehner, Keith S. Kaye, et al. · Contemporary Clinical Trials Communications
Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kδ) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block
2017 · Robert Wilson, Emily Jarvis, et al. · European Respiratory Journal
Works count: 18
Citation count: 333
H-index: 8
I10-index: 8
Year
Topic
Type